Apogee Therapeutics(APGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APGE Apogee Therapeutics

Trading 08-26 11:27:17 EDT

134.88

+0.03

+0.02%

High134.89	Low134.81	Vol615.60K
Open134.83	D1 Closing134.85	Amplitude0.06%
Mkt Cap10.16B	Tradable Cap7.84B	Total Shares75.34M
T/O83.01M	T/O Rate1.06%	Tradable Shares58.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APGE","market":"US","secType":"STK","nameCN":"Apogee Therapeutics","latestPrice":134.878,"timestamp":1787758031160,"preClose":134.85,"halted":0,"volume":615596,"delay":0,"changeRate":0.00020763811642559576,"floatShares":58137500,"shares":75339900,"eps":-4.34,"marketStatus":"Trading","change":0.028,"latestTime":"08-26 11:27:17 EDT","open":134.83,"high":134.885,"low":134.81,"amount":83010935.2342,"amplitude":0.000556,"askPrice":134.88,"askSize":1175,"bidPrice":134.87,"bidSize":938,"shortable":3,"etf":0,"ttmEps":-4.34,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787774400000},"marketStatusCode":2,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":134.85,"preHourTrading":{"tag":"盘前","latestPrice":134.83,"preClose":134.85,"latestTime":"09:29 EDT","volume":1211,"amount":163309.82885,"timestamp":1787750999983,"change":-0.02,"changeRate":-0.000148,"amplitude":0.001631},"postHourTrading":{"tag":"盘后","latestPrice":134.85,"preClose":134.85,"latestTime":"19:50 EDT","volume":6772,"amount":913203.2314,"timestamp":1787701829446,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.907515,"impliedVol":0.0651,"impliedVolPercentile":0.0438},"requestUrl":"/m/hq/s/APGE/","defaultTab":"news","newsList":[{"id":"2660492377","title":"AbbVie Closes USD 10B Multi-Tranche Senior Notes Offering to Fund Apogee Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2660492377","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660492377?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:31","pubTimestamp":1787085094,"startTime":"0","endTime":"0","summary":"AbbVie closes USD 10B multi-tranche senior notes offering to fund Apogee dealAbbVie completed a USD 10 billion senior notes offering, including senior floating rate notes due 2028.Deal included fixed-rate senior notes across eight maturities from 2028 to 2066, with coupons from 4.5% to 6.1%.Proceeds earmarked to fund part of the cash consideration for AbbVie’s planned acquisition of Apogee Therapeutics.If the Apogee deal is terminated, AbbVie must redeem the floating-rate notes and fixed-rate notes due 2028-2038 at 101%.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Se","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLbzVC04:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1718418525.SGD","LU0256863811.USD","FTXH","GLAM","IE00BSNM7G36.USD","LU0708994859.HKD","IE00B19Z3581.USD","JDOC","LU0128525929.USD","LU0395794307.EUR","LU2237443622.USD","LU0114720955.EUR","LU0472753341.HKD","LU0417517546.SGD","SG9999001440.SGD","FHLC","LU0965508806.USD","LU0965509283.SGD","LU1989771016.USD","SBIO","IYH","IE000BZT7R73.USD","AGNG","VHT","LU2237443549.SGD","IE000SO60NU8.SGD","LU0203347892.USD","LU0310799852.SGD","PPH","LU1093756325.SGD","LU2125909593.SGD","BK4534","PJP","APGE","LU1839511570.USD","RXL","ABBV","LU0211328371.USD","LU0553294199.USD","LU2129689605.HKD","MEDX","IE00B4R5TH58.HKD","IXJ","TRUH","LU2433249047.HKD","LU0795875086.SGD","XLV","BK4533","LU0545039389.USD","LU0234572021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659166348","title":"Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE) and Biogen (BIIB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659166348","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659166348?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:00","pubTimestamp":1786636814,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Apogee Therapeutics (APGE) and Biogen (BIIB). Apog...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-apogee-therapeutics-apge-and-biogen-biib-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-apogee-therapeutics-apge-and-biogen-biib-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z9Z06.USD","PBE","APGE","BK4585","LU0889565916.HKD","IE00B894F039.SGD","BK4581","LU0128526141.USD","LU0320765992.SGD","BK4532","SBIO","LABU","BK4139","BK4588","BK4533","BK4137","LU0109394709.USD","LU0234570918.USD","XBI","LU0053671581.USD","BMED","LU0029874061.USD","HCSG","IE00B19Z9P08.USD","XLV","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659139535","title":"U.S. Research Roundup-Airbnb, Five Below, Silgan Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2659139535","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659139535?lang=en_us&edition=fundamental","pubTime":"2026-08-13 14:48","pubTimestamp":1786603733,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan HoldingsAug 13 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Airbnb, Fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4N44A0G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COHC","ANRO","DVN","CRWG","PXI","BBY","COHH","AOSL","BGS","ANDG","CSV","CORD","DFTX","CBRS","AMWL","EAT","APA","AADX","SPRX","AMRZ","ARMK","ALGM","ATO","ACH","CHRD","COHX","ABNB","PKB","CSCO","LNG","ALL","AIQ","ARXS","COHR","CRWV","AMTM","GASZ","CRGY","AX","CC","AKAM","ACM","AIZ","APGE","BTGO","CAH","AHR","MLPI","CYTK","BESF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658869974","title":"BTIG Downgrades Apogee Therapeutics to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2658869974","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658869974?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:23","pubTimestamp":1786533826,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics (APGE) has an average rating of hold and mean price target of $132.44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658979608","title":"Apogee Therapeutics, Inc. : Btig Cuts to Neutral from Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2658979608","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658979608?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:43","pubTimestamp":1786531419,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","LU0053671581.USD","APGE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658979902","title":"Apogee Therapeutics Cut to Neutral from Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2658979902","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658979902?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:39","pubTimestamp":1786531140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APGE/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658947798","title":"RBC Capital Sticks to Their Hold Rating for Apogee Therapeutics (APGE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658947798","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658947798?lang=en_us&edition=fundamental","pubTime":"2026-08-12 09:45","pubTimestamp":1786499140,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Hold rating on Apogee Therapeutics on August 10 and set a price target of $135.00. The company’s sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-hold-rating-for-apogee-therapeutics-apge-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-hold-rating-for-apogee-therapeutics-apge-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948566","title":"Apogee Therapeutics Gelar Rapat Khusus Pemegang Saham Lewat Webcast Langsung","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948566","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948566?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:03","pubTimestamp":1786478583,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics gelar rapat khusus pemegang saham lewat webcast langsungApogee Therapeutics menggelar rapat khusus pemegang saham pada 11 Agustus 2026 untuk membahas transaksi merger yang diusulka","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDLRjqrs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","FTXH","IE00B3PB1722.GBP","LU0114720955.EUR","LU0256863811.USD","IE000MB6IJN5.SGD","LU0689472784.USD","PPH","BK4581","LU0417517546.SGD","LU1244550221.USD","IE000SO60NU8.SGD","LU1003077747.HKD","GLAM","RXL","SG9999003800.SGD","IE00B2B36J28.USD","LU0310800379.SGD","IYH","LU0124676726.USD","XLV","LU0289961442.SGD","FHLC","LU0949170772.SGD","JDOC","LU1496350502.SGD","ABBV","MEDX","LU1670627923.USD","LU0256863902.USD","LU2129689605.HKD","IXJ","SBIO","IE000F7OJYX1.SGD","IE0009355771.USD","LU0158827948.USD","LU0053671581.USD","LU0395794307.EUR","TRUH","LU2347655073.USD","IE00BGHQF631.EUR","AGNG","LU1162221912.USD","PJP","IE00B42XCP33.USD","LU0234572021.USD","VHT","APGE","IE00BSNM7G36.USD","IE00BVYPNW00.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658433917","title":"Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (RLMD), Surgery Partners (SGRY) and Apogee Therapeutics (APGE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658433917","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658433917?lang=en_us&edition=fundamental","pubTime":"2026-08-12 02:10","pubTimestamp":1786471809,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Relmada Therapeutics (RLMD), Surgery Partners (SGRY) and Apogee T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-relmada-therapeutics-rlmd-surgery-partners-sgry-and-apogee-therapeutics-apge-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-relmada-therapeutics-rlmd-surgery-partners-sgry-and-apogee-therapeutics-apge-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","RLMD","SGRY","BK4007","LABU","LU0029874061.USD","SBIO","LU0128526141.USD","LU0053671581.USD","BK4581","XBI","APGE","BK4585","PSIL","BK4588","XLV","HCSG","BK4185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658916683","title":"Wedbush Reaffirms Their Hold Rating on Apogee Therapeutics (APGE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658916683","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658916683?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:55","pubTimestamp":1786456517,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten maintained a Hold rating on Apogee Therapeutics today and set a price target of $135.00. Nierengarten covers the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-hold-rating-on-apogee-therapeutics-apge-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-hold-rating-on-apogee-therapeutics-apge-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658625839","title":"Apogee Therapeutics’ Merger Faces Significant Execution Risks, Potential $381 Million Termination Fee and Stock Price Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=2658625839","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658625839?lang=en_us&edition=fundamental","pubTime":"2026-08-11 14:00","pubTimestamp":1786428020,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics, Inc. (APGE) has disclosed a new risk, in the Corporate Activity and Growth category. Apogee Therapeutics, Inc. faces execution...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-merger-faces-significant-execution-risks-potential-381-million-termination-fee-and-stock-price-pressure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-merger-faces-significant-execution-risks-potential-381-million-termination-fee-and-stock-price-pressure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APGE","LU0053671581.USD","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933347","title":"Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933347","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933347?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:22","pubTimestamp":1786360965,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61070144/apogee-therapeutics-q2-eps-1-14-misses-1-05-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658387029","title":"Earnings Flash (APGE) Apogee Therapeutics Posts Q2 Net Loss $85.9M, vs. FactSet Est of $78.7M Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658387029","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658387029?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:17","pubTimestamp":1786360649,"startTime":"0","endTime":"0","summary":"Earnings Flash (APGE) Apogee Therapeutics Posts Q2 Net Loss $85.9M, vs. FactSet Est of $78.7M Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938940","title":"Apogee Net Loss Widens to $85.85 Million in Q2 FY26; R&D Expenses Rise to $67.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938940","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658938940?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:06","pubTimestamp":1786359994,"startTime":"0","endTime":"0","summary":"Apogee net loss widens to $85.85 million in Q2 FY26; R&D expenses rise to $67.3 millionApogee Therapeutics posted a Q2 2026 net loss of $85.85 million, widening from $66.1 million a year earlier.R&D e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDLsYr5J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000MB6IJN5.SGD","LU0069063385.USD","LU1291159041.SGD","FTXH","GLAM","LU2237443465.HKD","IE00BVYPNV92.GBP","JDOC","LU0289739699.SGD","IE0009355771.USD","LU0942090050.USD","IE0002270589.USD","IE00B3PB1722.GBP","IE00BLSP4452.SGD","NDAQ","FHLC","LU0965508806.USD","SBIO","IYH","AGNG","VHT","LU2023251221.USD","PPH","BK4581","PJP","LU2468319806.SGD","APGE","LU1839511570.USD","IE00BLSP4239.USD","ABBV","LU0211328371.USD","LU2125909247.SGD","RXL","LU0985320562.USD","LU0912757837.SGD","BCDF","SG9999014013.SGD","IE00BJT1NW94.SGD","MEDX","IE00BJJMRZ35.SGD","IXJ","TRUH","LU2433249047.HKD","LU1037948897.HKD","XLV","LU1732800096.USD","BK4533","BK4559","LU2095319765.USD","LU2089283258.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658980067","title":"Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658980067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658980067?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA10RXHS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE","LU0053671581.USD","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658893387","title":"Apogee Therapeutics, - Q2 2026 Net Loss $85.90 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2658893387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658893387?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA10RXHS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053671581.USD","APGE","SBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657624586","title":"Apogee Therapeutics CMO Carl Dambkowski Disposes of USD 737,935 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2657624586","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657624586?lang=en_us&edition=fundamental","pubTime":"2026-08-08 08:00","pubTimestamp":1786147253,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics CMO Carl Dambkowski disposes of USD 737,935 in common sharesApogee Therapeutics Chief Medical Officer Carl Dambkowski sold 5,500 shares on Aug. 5 at USD 134.17.He exercised stock o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260808:nNDL13c7rF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Apogee Therapeutics CMO Carl Dambkowski Disposes of USD 737,935 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","APGE","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633115","title":"Market Chatter: AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633115","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633115?lang=en_us&edition=fundamental","pubTime":"2026-08-05 01:40","pubTimestamp":1785865235,"startTime":"0","endTime":"0","summary":"AbbVie  has commenced a $10 billion investment-grade bond sale to help finance its pending acquisition of Apogee Therapeutics , Bloomberg reported Tuesday, citing people with direct knowledge of the matter.The offering, which includes bonds maturing in two to 40 years, has drawn about $63 billion of peak demand, the report said, citing the people.AbbVie didn't immediately reply to a request for comment from MT Newswires.Price: 243.24, Change: -1.86, Percent Change: -0.76","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["US6M.BOND","APGE","LU1244550221.USD","MEDX","AGNG","LU0211328371.USD","IXJ","LU1267930490.SGD","LU0310799852.SGD","VHT","LU0912757837.SGD","LU1923622614.USD","IYH","US7Y.BOND","LU0203345920.USD","FHLC","LU1585245621.USD","US5Y.BOND","US2Y.BOND","JDOC","LU0859254822.USD","TRUH","XLV","TLTW","LU1037948541.HKD","US10Y.BOND","SBIO","US3Y.BOND","LU2087621335.USD","US12M.BOND","IE00BJJMRZ35.SGD","US30Y.BOND","LU0943347566.SGD","LU1162221912.USD","PPH","PJP","LU1551013342.USD","FTXH","TLT","LU0511384066.AUD","LU1934455863.HKD","GLAM","TMF","LU1093756168.USD","RXL","LU2347655073.USD","IE00BVYPNV92.GBP","ABBV","LU0738911758.USD","LU0395794307.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656590975","title":"Abbvie Seeks at Least $8 Billion in Debt to Fund Apogee Deal - Bloomberg News","url":"https://stock-news.laohu8.com/highlight/detail?id=2656590975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656590975?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:17","pubTimestamp":1785849448,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4410VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0211328371.USD","IXJ","IYH","APGE","LU0198837287.USD","ABBV","LU1551013425.SGD","PJP","FHLC","LU2089284900.SGD","LU2433249047.HKD","LU0053671581.USD","MEDX","LU2237443622.USD","IE000MB6IJN5.SGD","IE00BFTCPJ56.SGD","LU0861579265.USD","LU1244550494.USD","SG9999015952.SGD","RXL","LU2357627491.SGD","LU0058720904.USD","LU1093756325.SGD","IE00B42XCP33.USD","LU0203347892.USD","FTXH","LU0122379950.USD","TRUH","PPH","LU0726765562.USD","LU0661504455.SGD","LU2468319806.SGD","LU0289739343.SGD","SBIO","LU0029864427.USD","LU1551013342.USD","LU0820561909.HKD","LU0965508806.USD","IE00BVYPNW00.USD","SG9999003800.SGD","IE00BDGV0183.EUR","LU2125909593.SGD","LU1989771016.USD","XLV","AGNG","GLAM","VHT","LU1670628061.USD","JDOC","LU0289961442.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656550225","title":"Abbvie : Plans to Use Note Offering Proceeds for Apogee Therapeutics Acquisition Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2656550225","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656550225?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:20","pubTimestamp":1785846049,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4411E4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1585245621.USD","JDOC","LU1037948541.HKD","VHT","LU1244550577.SGD","IE00BGHQF631.EUR","SBIO","LU0795875169.SGD","FHLC","LU0708994859.HKD","LU1732799900.SGD","IE00BVYPNV92.GBP","LU2023251221.USD","LU1074936037.SGD","AGNG","IE000F7OJYX1.SGD","IE0002141913.USD","LU2237443895.HKD","RXL","SG9999011175.SGD","LU1934455194.USD","GLAM","LU1718418525.SGD","PPH","TRUH","IYH","LU0198837287.USD","MEDX","LU0289739343.SGD","LU0726765562.USD","LU2089284900.SGD","LU1291159041.SGD","LU0868494617.USD","XLV","LU0320765646.SGD","PJP","LU1934455277.USD","IE00BFTCPJ56.SGD","LU2112291526.USD","LU2125909593.SGD","LU1023059063.AUD","LU0211327993.USD","IE00B42XCP33.USD","FTXH","APGE","LU1057294990.SGD","LU0395794307.EUR","IXJ","LU2089984988.USD","ABBV"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apogeetherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.0042},{"period":"3month","weight":0.7344},{"period":"6month","weight":0.9518},{"period":"1year","weight":2.6505},{"period":"ytd","weight":0.7866}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.006689},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.043968},{"month":3,"riseRate":1,"avgChangeRate":0.433037},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.069219},{"month":5,"riseRate":0,"avgChangeRate":-0.056063},{"month":6,"riseRate":0.666667,"avgChangeRate":0.221133},{"month":7,"riseRate":0.666667,"avgChangeRate":0.042938},{"month":8,"riseRate":0.75,"avgChangeRate":0.019738},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056277},{"month":10,"riseRate":0.333333,"avgChangeRate":0.038958},{"month":11,"riseRate":0.666667,"avgChangeRate":0.091668},{"month":12,"riseRate":1,"avgChangeRate":0.161393}],"exchange":"NASDAQ","name":"Apogee Therapeutics","nameEN":"Apogee Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apogee Therapeutics(APGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Apogee Therapeutics(APGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Apogee Therapeutics,APGE,Apogee Therapeutics股票,Apogee Therapeutics股票老虎,Apogee Therapeutics股票老虎国际,Apogee Therapeutics行情,Apogee Therapeutics股票行情,Apogee Therapeutics股价,Apogee Therapeutics股市,Apogee Therapeutics股票价格,Apogee Therapeutics股票交易,Apogee Therapeutics股票购买,Apogee Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apogee Therapeutics(APGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Apogee Therapeutics(APGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction